Cargando…

SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing

Prostate cancer remains one of the leading causes of cancer death in men around the world, regardless of intense research and development of novel therapies in the last 10 years. One of the new avenues that has been tested ⿿ inhibition of angiogenesis ⿿ has been disappointing so far in clinical stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Mavrou, Athina, Oltean, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876767/
https://www.ncbi.nlm.nih.gov/pubmed/26995304
http://dx.doi.org/10.1016/j.phrs.2016.03.013
_version_ 1782433288181252096
author Mavrou, Athina
Oltean, Sebastian
author_facet Mavrou, Athina
Oltean, Sebastian
author_sort Mavrou, Athina
collection PubMed
description Prostate cancer remains one of the leading causes of cancer death in men around the world, regardless of intense research and development of novel therapies in the last 10 years. One of the new avenues that has been tested ⿿ inhibition of angiogenesis ⿿ has been disappointing so far in clinical studies in spite of strong evidence that determinants of angiogenesis (e.g. vascular endothelial growth factor) are strongly associated with disease progression. One of the reasons for these outcomes may be our poor understanding of the biology of angiogenesis in prostate cancer (and probably other cancers as well) resulting in inhibition of both detrimental and favourable molecules. We discuss here novel targeted and more specific approaches to inhibit angiogenesis in prostate cancer as well as a completely new therapeutic modality to do this ⿿ modulation of alternative splicing ⿿ that may be applicable to other molecules/biological processes as well.
format Online
Article
Text
id pubmed-4876767
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-48767672016-06-01 SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing Mavrou, Athina Oltean, Sebastian Pharmacol Res Invited Perspective Prostate cancer remains one of the leading causes of cancer death in men around the world, regardless of intense research and development of novel therapies in the last 10 years. One of the new avenues that has been tested ⿿ inhibition of angiogenesis ⿿ has been disappointing so far in clinical studies in spite of strong evidence that determinants of angiogenesis (e.g. vascular endothelial growth factor) are strongly associated with disease progression. One of the reasons for these outcomes may be our poor understanding of the biology of angiogenesis in prostate cancer (and probably other cancers as well) resulting in inhibition of both detrimental and favourable molecules. We discuss here novel targeted and more specific approaches to inhibit angiogenesis in prostate cancer as well as a completely new therapeutic modality to do this ⿿ modulation of alternative splicing ⿿ that may be applicable to other molecules/biological processes as well. Elsevier 2016-05 /pmc/articles/PMC4876767/ /pubmed/26995304 http://dx.doi.org/10.1016/j.phrs.2016.03.013 Text en © 2016 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Invited Perspective
Mavrou, Athina
Oltean, Sebastian
SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing
title SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing
title_full SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing
title_fullStr SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing
title_full_unstemmed SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing
title_short SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing
title_sort srpk1 inhibition in prostate cancer: a novel anti-angiogenic treatment through modulation of vegf alternative splicing
topic Invited Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876767/
https://www.ncbi.nlm.nih.gov/pubmed/26995304
http://dx.doi.org/10.1016/j.phrs.2016.03.013
work_keys_str_mv AT mavrouathina srpk1inhibitioninprostatecanceranovelantiangiogenictreatmentthroughmodulationofvegfalternativesplicing
AT olteansebastian srpk1inhibitioninprostatecanceranovelantiangiogenictreatmentthroughmodulationofvegfalternativesplicing